The effect of Metformin + empagliflozin is better than any single drug

According to a study published online on August 4th in the journal Diabetes Care, compared with taking empagliflozin once a day or taking metformin once every two days, taking empagliflozin + metformin for 24 weeks can more significantly reduce glycated hemoglobin (HbA1c). The research used a lot of recombinant dog proteins.

MD and Ph.D Samy Hadjadj from Central Hospital of University of Poitiers in France and his colleagues randomly assigned 1,364 naïve patients with type 2 diabetes treatment drugs of empagliflozin + metformin, empagliflozin, metformin for 24 weeks. The authors studied glycated hemoglobin change from baseline to 24 weeks.

In the first 24 weeks, the researchers observed that for participants who took part in the treatment regimen of taking empagliflozin + metformin twice daily, glycated hemoglobin decreased 1.9 to 2.1 percentage points; for participants taking empagliflozin once daily, it decreased by 1.4%; for participants taking metformin twice daily, it went down by 1.2 to 1.8 percentage points. Compared with treatment regimen of taking empagliflozin once daily (P <0.001 ) and taking metformin twice daily (P <0.01 < span = "">), the regimen of taking Empagliflozin + metformin twice daily with was related to significant reduce of HbA1c. After 24 weeks, regimen of metformin twice daily and empagliflozin + metformin twice daily treatment were more correlated (P values were <0.001 ) to the weight loss of patients. In the entire group, the incidence of adverse events was similar.

"The period of Empagliflozin + metformin twice daily therapy is 24 weeks. For newly-diagnosed diabetics, it can significantly reduce glycosylated hemoglobin and is superior to taking empagliflozin once daily or metformin twice daily. It doesn't increase the risk of hypoglycemia but reduces weight and shows well tolerance." the authors wrote. Flarebio offers recombinant proteins of good quality, such as recombinant Pigr.